TARA Biosystems harnesses innovations in stem cell biology and tissue engineering to generate in vitro biology that recapitulates human physiology with unprecedented fidelity. Our highly versatile and robust platform captures integrated physiologic endpoints of human cardiac function across a wide repertoire of cardiac disease phenotypes. Our data facilitates decisive evaluation of the efficacy and risk of novel medicines, increasing the probability of success and decreasing long timeframes associated with traditional drug discovery efforts. Safer and more effective new medicines that rapidly make it to market means better health and longer lives, and we believe that benefits people everywhere.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
06/23/20 | $10,000,000 | Series A-2 |
Alexandria Venture Investments DEFTA Partners LifeForce Capital Merieux Equity Partners New York Ventures OMX Ventures Partnership Fund for New York City Tachyon Ventures Trancos Ventures | undisclosed |